lapatinib has been researched along with Bile Duct Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, XD; Li, WD; Mou, HB; Shen, YJ; Shi, JP; Wang, K; Yao, M; Zhang, T | 1 |
| Almenara, JA; Campbell, DJ; Dewitt, JL; Oyesanya, RA; Sirica, AE; Zhang, Z | 1 |
| Andersen, JB; Avital, I; Barbour, A; Blechacz, BR; Conner, EA; Factor, VM; Gillen, MC; Komuta, M; Roberts, LR; Roskams, T; Spee, B; Thorgeirsson, SS | 1 |
| Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D | 1 |
1 review(s) available for lapatinib and Bile Duct Neoplasms
| Article | Year |
|---|---|
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Belgium; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chi-Square Distribution; Cholangiocarcinoma; Cluster Analysis; ErbB Receptors; Female; Gene Expression Profiling; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lapatinib; Laser Capture Microdissection; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Oligonucleotide Array Sequence Analysis; Patient Selection; Phenotype; Precision Medicine; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Queensland; Quinazolines; ras Proteins; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Trastuzumab; Tumor Microenvironment; United States | 2012 |
1 trial(s) available for lapatinib and Bile Duct Neoplasms
| Article | Year |
|---|---|
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis | 2008 |
2 other study(ies) available for lapatinib and Bile Duct Neoplasms
| Article | Year |
|---|---|
Trastuzumab, not lapatinib, has therapeutic effects on Chinese patients with HER2-positive cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bile Duct Neoplasms; China; Cholangiocarcinoma; Female; Humans; Lapatinib; Male; Receptor, ErbB-2; Retreatment; Trastuzumab; Treatment Failure | 2018 |
Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; Signal Transduction; Tyrphostins | 2010 |